Top Stories for the Week of Oct. 29th 2007

Friday, November 2, 2007 03:08 PM

Top News

 

NEJM Takes Shots at CROs

A recent New England Journal of Medicine (NEJM) Perspective piece criticized the clinical trials industry for its reliance on contract research organizations (CROs). The piece describes the rapid growth in the CRO industry, questions the quality of research data it generates and cites various clinical trials that have shed some negative light on CRO-run studies.

PPD Continues Geographic Expansion While Reporting Strong Third Quarter

While reporting a 14% increase in its third quarter revenue, Wilmington, N.C.-based contract research organization (CRO) PPD opened new offices on four continents.The company launched offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru and Lisbon, Portugal. PPD has also expanded its presence in India with new office space.
    
Other breaking news...     

Company Profile: An interview with Ginger Clasby, vice president business development, Promedica International

To read the full articles for this issue or for more information on these and other breaking stories, pleaseclick herefor subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs